1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Shield Therapeutics plc

Shield Therapeutics plc

STX.L
Shield Therapeutics plcGB flagLondon Stock Exchange
6.10
GBp
-0.05
- -
65.24MMarket Cap
Shield Therapeutics plc
STX.L
(London Stock Exchange)

Recent

price

6.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
0.01
0.13
0.01
0.12
0.01
0.02
0.02
0.04
- -
Revenue per Share
-0.61
-0.82
-0.18
-0.23
-0.02
-0.1
-0.03
-0.12
-0.21
-0.05
-0.03
- -
Basic EPS, GAAP
-0.16
-0.15
-0.13
-0.19
- -
-0.04
-0.02
-0.11
-0.1
-0.06
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.07
-1.63
-0.72
-0.88
-0.81
-0.92
-0.98
-0.67
-0.82
-0.33
-0.26
- -
Book Value per Share
-0.89
-0.66
0.23
0.13
0.1
0.02
0.03
0.09
-0.03
- -
-0.02
- -
Tangible Book Value per Share
33
43
104
116
120
120
121
221
238
666
906
- -
Basic Weighted Avg Shares
- -
- -
- -
1
15
1
14
2
5
13
32
50
Sales/Revenue/Turnover
- -
- -
-4,098.68
-3,289.01
-43.42
-1,256.61
-20.74
-1,336.01
-575.49
-239.44
-71.08
-20.22
Operating Margin (%)
- -
- -
2
3
3
3
4
3
3
1
1
1
Depreciation Expense
-20
-35
-19
-26
-2
-12
-4
-27
-50
-33
-27
-18
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-4,939.47
-3,075.04
-15.08
-1,223.92
-25.32
-1,295.46
-905.42
-254.44
-84.47
-35.52
Profit Margin (%)
-13
-2
24
15
12
3
4
19
-1
18
5
-5
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
7
20
26
30
LT Debt
-28
-28
60
56
51
42
41
55
7
15
-1
-15
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
66.1%
202.35%
1,044.8%
Free Cash Flow
320.5%
224.13%
-49.98%
Net Income, GAAP
88.48%
128.38%
-35.05%
Sales/Revenue/Turnover
- -
84.21%
54.45%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
13
2024
- -
- -
- -
- -
32
2025
- -
- -
- -
- -
50

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.05
2024
- -
- -
- -
- -
-0.03
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Grown Rogue International Inc. (GRIN.CN)
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ)
Fusen Pharmaceutical Company Limited (1652.HK)
PT Industri Jamu dan Farmasi Sido Muncul Tbk (SIDO.JK)
Octavia Wellness Inc. (OCTVV)
Kamada Ltd. (KMDA.TA)
Business
Shield Therapeutics plc (LSE:STX) is a UK-based commercial-stage specialty pharmaceutical company focused on developing and commercializing treatments for iron deficiency with or without anemia. The company offers ACCRUFeR®/Feraccru® (ferric maltol), a novel, stable, non-salt-based oral iron therapy indicated for adults across multiple therapeutic categories including inflammatory bowel disease, renal disease, and general iron deficiency; it is approved in the United States, European Union, United Kingdom, Canada, Australia, and Switzerland. Operations span North America, Europe, and Asia-Pacific through partnerships, with headquarters in Gateshead Quays, England; founded in 2008, subsidiaries include Shield Therapeutics Inc (US), Shield TX (Switzerland) AG, Shield TX (UK) Limited, and Phosphate Therapeutics Limited. Recent developments include an 80% revenue increase to $21.4 million in the first half of 2025 driven by ACCRUFeR® growth, particularly as the top branded prescription oral iron in the US; a £1.5 million placing in September 2025 via 20 million new shares to support US expansion and working capital; and a $5.7 million cash receipt from AOP Health in exchange for China milestone rights. Strategic alliances encompass exclusive licenses with Viatris for US co-commercialization, Kye Pharmaceuticals for Canada (launched March 2025), VITAL-NET for Japan (April 2025, $665,000 upfront), Beijing Aosaikang Pharmaceutical for China/Hong Kong/Macau/Taiwan (Phase 3 completed for IBD patients, NDA filing pending), and Korea Pharma for South Korea. These partnerships and financings bolster global commercialization amid progress toward cash flow positivity by end-2025.